Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27458712 | 0.87 | CYP19A1 (0.43) | CYP19A1ALDH1A1CALM1AKR1B1DAO | |
| SCHEMBL11098567 | 0.86 | CYP19A1 (0.50) | CYP19A1ALDH1A1CALM1AKR1B1DAO | |
| SCHEMBL9491787 | 0.85 | CYP19A1 (0.68) | CYP19A1ALDH1A1CALM1AKR1B1DAO | |
| SCHEMBL627823 | 0.80 | ALDH1A1 (0.58) | CYP19A1ALDH1A1CALM1AKR1B1TSHR | |
| SCHEMBL31347513 | 0.80 | LMNA (0.44) | CYP19A1ALDH1A1PTGS2TSHRMAPK1 | |
| SCHEMBL177862 | 0.79 | TAAR1 (0.67) | TAAR1 | |
| SCHEMBL30169530 | 0.79 | TAAR1 (0.67) | TAAR1 | |
| SCHEMBL467237 | 0.78 | ALDH1A1 (0.55) | CYP19A1ALDH1A1CALM1AKR1B1TSHR | |
| SCHEMBL427550 | 0.78 | CYP19A1 (0.55) | CYP19A1ALDH1A1CALM1AKR1B1DAO | |
| SCHEMBL5871310 | 0.77 | CYP11B1 (0.43) | FGFR1KDRCYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839942-B | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2024-08-23 | — | — | CN | disclosed |
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-04-16 | — | — | US | disclosed |
| CN-112584898-B | P2X 3 Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3827004-B1 | 4-(1,3,4-OXADIAZOLE-2-YL)PYRIDINE-2(1H)-ONE DERIVATIVES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS FOR THE TREATMENT OF E.G. INFECTIONS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-10-11 | — | — | EP | disclosed |
| CN-114630832-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-06-24 | — | — | US | disclosed |
| EP-3827004-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2021-06-02 | — | — | EP | disclosed |
| CN-112839942-A | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-05-25 | — | — | CN | disclosed |
| WO-2021093758-A1 | PYRIMIDO DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093758-A1 | PYRIMIDO DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007044796-A2 | PYRIDAZINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | CYP19A1 787/4885ALDH1A1 201/4885CALM1 3043/4885 |
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC3 | CYP19A1 525/4885ALDH1A1 306/4885CALM1 3480/4885 |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | CYP19A1 525/4885ALDH1A1 306/4885CALM1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.